Best Practices Extend Beyond GLP for Investigational New Drug (IND) Enabling Studies Best Practices Extend Beyond GLP for Investigational New Drug (IND) Enabling Studies By Ray Peck|2020-01-11T09:45:52-05:00May 8th, 2019|Generic & Commercial Drug Manufacturing Services, Uncategorized|
